Trials (Aug 2023)

Evaluation of interventions to prevent vasovagal reactions among whole blood donors: rationale and design of a large cluster randomised trial

  • Amy McMahon,
  • Stephen Kaptoge,
  • Matthew Walker,
  • Susan Mehenny,
  • Philippe T Gilchrist,
  • Jennifer Sambrook,
  • Naim Akhtar,
  • Michael Sweeting,
  • Angela M Wood,
  • Kathleen Stirrups,
  • Ryan Chung,
  • Sarah Fahle,
  • Elisha Johnson,
  • Donna Cullen,
  • Rosemary Godfrey,
  • Shannon Duthie,
  • Louise Allen,
  • Paul Harvey,
  • Michael Berkson,
  • Elizabeth Allen,
  • Nicholas A Watkins,
  • John R Bradley,
  • Nathalie Kingston,
  • Gail Miflin,
  • Jane Armitage,
  • David J Roberts,
  • John Danesh,
  • Emanuele Di Angelantonio

DOI
https://doi.org/10.1186/s13063-023-07473-z
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Background Vasovagal reactions (VVRs) are the most common acute complications of blood donation. Responsible for substantial morbidity, they also reduce the likelihood of repeated donations and are disruptive and costly for blood services. Although blood establishments worldwide have adopted different strategies to prevent VVRs (including water loading and applied muscle tension [AMT]), robust evidence is limited. The Strategies to Improve Donor Experiences (STRIDES) trial aims to reliably assess the impact of four different interventions to prevent VVRs among blood donors. Methods STRIDES is a cluster-randomised cross-over/stepped-wedge factorial trial of four interventions to reduce VVRs involving about 1.4 million whole blood donors enrolled from all 73 blood donation sites (mobile teams and donor centres) of National Health Service Blood and Transplant (NHSBT) in England. Each site (“cluster”) has been randomly allocated to receive one or more interventions during a 36-month period, using principles of cross-over, stepped-wedge and factorial trial design to assign the sequence of interventions. Each of the four interventions is compared to NHSBT’s current practices: (i) 500-ml isotonic drink before donation (vs current 500-ml plain water); (ii) 3-min rest on donation chair after donation (vs current 2 min); (iii) new modified AMT (vs current practice of AMT); and (iv) psychosocial intervention using preparatory materials (vs current practice of nothing). The primary outcome is the number of in-session VVRs with loss of consciousness (i.e. episodes involving loss of consciousness of any duration, with or without additional complications). Secondary outcomes include all in-session VVRs (i.e. with and without loss of consciousness), all delayed VVRs (i.e. those occurring after leaving the venue) and any in-session non-VVR adverse events or reactions. Discussion The STRIDES trial should yield novel information about interventions, singly and in combination, for the prevention of VVRs, with the aim of generating policy-shaping evidence to help inform blood services to improve donor health, donor experience, and service efficiency. Trial registration ISRCTN: 10412338. Registration date: October 24, 2019.

Keywords